This may well be the best thread to keep front and centre, The detail is significant and the most current info surrounding MND.
The results are again resoundingly positive but was over shadowed with the CR announcement later in the day.
Really was expecting a little traction from this 2nd Cohort update thinking it would stimulate a run or at least 1 to 2 cents?
As seen last week with Bio's pulling 40% to 80% gains delivering positive data to market.
The last week of May is upon us dropping us into June next week and the hurdle for the for the 20c oppes will require a circa 3c a Month increase in SP to be at the strike price in October..
To date all of the last 12 months of positive data has seen our SP decrease from a January 9.7c high and the CR took the wind out of a climb to 11.5c.
With completion of the K9 Trial scheduled for Mid Year the Company may start peppering the news with updates informing the Market that PAA has been in commercial discussions for an extended period of time now of 3 years we should see an agreement crystalise that will benefit PAA as well as deliver SH value..
Cohort 2 and Cohort 3 for the Human MND Trial have continued to take an escalating dose of MPL according to the ANZCTR and the DSMB have not reported any adverse effects to date , so the hunt for the Goldilocks dose will be nearing completion, then all Patients will continue at the Optimum Dose for 6 months.. The News of additional patients reaching stasis or is the original trial patient has possibly shown actual improvement or reduction in ALS and MND symptoms would be hugely significant and incredibly valuable.
I think we can say the OHD reactor is back in the cupboard?
Covid still raging through out the world and in Australia with 5,400 new cases a day, so a little confused that PAA desire to Trial in Poland which borders Ukraine??? simple solutions required maybe, holding the Trial in Australia would certainly simplify , transportation, Language barriers and being on the border of a modern War..
COVID-19 case notifications
- Over the last week, 38,226 cases of COVID-19 were reported across Australia, an average of 5,461 cases per day.
COVID-19 cases and 7 day rolling average, 01 Jan 2022 to 16 May 2023
Source: Jurisdictional reporting as at 17 May 2023. Please note that due to rounding, jurisdiction averages may not sum exactly to national averages.
Trial numbers are quite small for testing covid as its a Virus so the mechanism of action is easily monitored and defined. 16 to 24 patients and the trials are very swift, they have to be to effect the virus before it runs its natural 10 to 14 day term.
For me the current value of an Oral Covid Tablet would be hugely significant $$$$$$$$$$$$$
( Covid which is a SARs 1 virus one of 300 that effect Humans)
Plus PAA have a Patent for MPL vs Covid /SARs 1 and SARs2 antiviral applications
2020 was a huge year with multiple ASX Announcements confirming MPL positive effect on Covid
Monepantel Anti-viral Activity Against SARS-CoV-2 Confirmed• Further testing demonstrates Monepantel (MPL) and monepantel sulfone (MPLS)
reduce SARS-CoV-2, the causative agent of COVID-19.
• Experimental results to date include repeat studies in VERO cells by two independent
laboratories and evaluation of SARS-CoV-2 anti-viral activity in human Calu-3 cells.
• MPL and MPLS have reduced virus burden regardless of laboratory, cell type or timing
of treatment (prior or post-infection).
•
Preparations for a Phase 1 clinical trial in humans in progress.9 September 2020 – Perth, Australia: PharmAust Ltd (ASX
AA), a clinical-stage oncology
company, is pleased to announce a successful second repeat of its in vitro anti-viral
confirmatory testing demonstrating anti-SARS-CoV-2 activity of both monepantel (MPL) and
monepantel sulfone (MPLS).
The SP quickly ran up to 26c on the back of the Covid data confirmation
WEHI 1
WEHI 2
Biolabs 360
Leiden
ONJF + WEHI additional Virals , Hep etc.
Now the kitty has a little more tucked away best PAA start pursuing & confirming what we all believe to know that MPL is ready for trialing ASAP,, or funds will just be eroded over time again , PAA utilises circa $660 a Quarter on wages and Administration so best we get Positive Human Results to strengthen the SP and place the Oppies in the money as the $15m from the Oppies is desperately required to begin Human Oncology Trials, which by very nature are
expensive, Regrettably there is a never ending pool of Cancer sufferers so would expect the MPL VS Cancer Trial to be held in Australia..
Huge Month ahead for Pharmaust , some would say "Transitional" " with a Commercial Outcome on the near Horizon" "Plus additional MND Data to strengthen Value of Pharmaust and benefit SH directly"
NZT
(20min delay)